000166693 001__ 166693
000166693 005__ 20240229133528.0
000166693 0247_ $$2doi$$a10.21873/invivo.12238
000166693 0247_ $$2pmid$$apmid:33402456
000166693 0247_ $$2ISSN$$a0258-851X
000166693 0247_ $$2ISSN$$a1791-7549
000166693 037__ $$aDKFZ-2021-00046
000166693 041__ $$aeng
000166693 082__ $$a610
000166693 1001_ $$0P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aZwicker, Felix$$b0$$eFirst author$$udkfz
000166693 245__ $$aIn Vivo Evaluation of Combined CK2 Inhibition and Irradiation in Human WiDr Tumours.
000166693 260__ $$aKapandriti, Attiki$$bIIAR$$c2021
000166693 3367_ $$2DRIVER$$aarticle
000166693 3367_ $$2DataCite$$aOutput Types/Journal article
000166693 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1612508725_8988
000166693 3367_ $$2BibTeX$$aARTICLE
000166693 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000166693 3367_ $$00$$2EndNote$$aJournal Article
000166693 500__ $$a#EA:E050#LA:E055#
000166693 520__ $$aCasein kinase 2 (CK2) which sustains multiple pro-survival functions in cellular DNA-damage response, is strictly regulated in normal cells but elevated in cancer. CK2 is considered as a potential therapeutic target, and its inhibition has been associated with radiosensitization in mammalian cells in vitro. Here, we investigated potential radiosensitization by CK2 inhibition in vivo.The effect of CK2 inhibition in vivo was investigated in human WiDr-xenograft tumours grown subcutaneously on BALB/c nu/nu mice with and without fractionated irradiation. CK2 inhibition was performed using the specific inhibitor tetra-bromobenzotriazole (TBB). Histological examinations included staining for apoptosis and double-strand breaks.Both TBB treatment alone and radiation alone significantly reduced tumour growth, which was reflected by increased apoptosis rates. However, TBB treatment did not boost radiation-induced tumour growth suppression in combined treatment, although the apoptosis rate increased and repair of double-strand breaks was reduced. This was in stark contrast to previous data on in vitro radiosensitization.The absence of radiosensitization by CK2 inhibition should be investigated in different tumour models.
000166693 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000166693 588__ $$aDataset connected to CrossRef, PubMed,
000166693 650_7 $$2Other$$aCK2 inhibition
000166693 650_7 $$2Other$$aTBB
000166693 650_7 $$2Other$$ahuman WiDr tumours
000166693 650_7 $$2Other$$airradiation
000166693 650_7 $$2Other$$atetra-bromobenzotriazole
000166693 7001_ $$aHauswald, Henrik$$b1
000166693 7001_ $$aWeber, Klaus-Josef$$b2
000166693 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, JÜrgen$$b3$$udkfz
000166693 7001_ $$0P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aHuber, Peter$$b4$$eLast author$$udkfz
000166693 773__ $$0PERI:(DE-600)2492569-X$$a10.21873/invivo.12238$$gVol. 35, no. 1, p. 111 - 117$$n1$$p111 - 117$$tIn vivo$$v35$$x1791-7549$$y2021
000166693 909CO $$ooai:inrepo02.dkfz.de:166693$$pVDB
000166693 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca89260a6f950d2149ad4aa50732aa2c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000166693 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000166693 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3291aaac20f3d603d96744c1f0890028$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000166693 9130_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000166693 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000166693 9141_ $$y2021
000166693 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bIN VIVO : 2018$$d2020-08-32
000166693 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-32
000166693 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000166693 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x1
000166693 980__ $$ajournal
000166693 980__ $$aVDB
000166693 980__ $$aI:(DE-He78)E050-20160331
000166693 980__ $$aI:(DE-He78)E055-20160331
000166693 980__ $$aUNRESTRICTED